替吉奥联合多西他赛方案维持治疗非小细胞肺癌的临床疗效及安全性分析

目的 观察替吉奥联合多西他赛方案维持治疗非小细胞肺癌的临床疗效,并分析临床治疗的安全性.方法 将88例非小细胞肺癌患者随机分为对照组和实验组,各44例.对照组患者给予每日2次饭后口服替吉奥80 mg/m2治疗,连服14天,停药7天.实验组在对照组的基础上给予每周1次多西他赛40 mg/m2溶于250 ml生理盐水静脉滴注1 h,连用6周,停药2周.维持治疗3个周期后,评价患者临床疗效及安全性,并分析患者1年生存情况.结果与对照组相比,实验组患者的临床治疗有效率为47.73%,明显高于对照组的22.73%(P<0.05).2组患者临床不良反应主要表现为恶心呕吐、腹泻、肝功能损伤、贫血、血小板及白细胞数目减少等症状,但均为轻中度,经治疗后均可缓解(P>0.05).实验组患者1年生存率为72.73%,明显高于对照组的52.27%(P<0.05).结论 替吉奥联合多西他赛方案维持治疗非小细胞肺癌的临床疗效肯定,可有效缓解患者的临床症状,且不良反应较少.

Clinical Efficacy and Safety of Tegafur Combined with Docetaxel in Maintenance Treatment of Non-small Cell Lung Cancer

Objective To study the clinical efficacy and safety of tegafur combined with docetaxel in maintenance treat -ment of non-small cell lung cancer .Methods 88 patients with non-small cell lung cancer were randomly divided into the control group and the experimental group ,44 cases in each group .The control group received 2 times a day after oral administration of Di-ego 80 mg/m2 treatment,even for 14 days,withdrawal 7 days.In the experimental group ,40 mg/m2 of docetaxel was dissolved in 250 ml saline for 1 h,once every 6 weeks,and stopped for 2 weeks on the basis of the control group .After 3 cycles of maintenance treatment,the clinical efficacy and safety of the patients were evaluated and 1-year survival was analyzed .Results Compared with the control group,the effective rate of clinical treatment was 47.73%in the experimental group,which was significantly high-er than that of the control group (22.73%,P<0.05).The clinical adverse reactions were mainly manifested as nausea ,vomiting, diarrhea,liver injury,anemia,platelet count and leukocyte count ,but were mild to moderate (P>0.05).1-year survival rate was 72.73%in the experimental group,which was significantly higher than that of the control group (52.27%,P<0.05).Conclu-sion Tegafur combined with docetaxel scheme maintenance in treatment of non -small cell lung cancer is effective ,the treatment can effectively relieve the clinical symptoms ,with less adverse reactions .